Comparative pharmacokinetics of YM-13115, ceftriaxone, and ceftazidime in rats, dogs, and rhesus monkeys.
The pharmacokinetics of YM-13115, ceftriaxone, and ceftazidime were studied in rats, dogs, and rhesus monkeys (only YM-13115 and ceftriaxone were studied in rhesus monkeys). The plasma half-lives in rats were 48 min for YM-13115, 34 min for ceftriaxone, and 14 min for ceftazidime. In dogs, they were 21.9 min for YM-13115, 50.7 min for ceftriaxone, and 49.0 min for ceftazidime. In monkeys, they were 5.30 h for YM-13115 and 3.40 h for ceftriaxone. The 24-h urinary recoveries in rats were 26.7% of the dose for YM-13115, 32.0% for ceftriaxone, and 97.1% for ceftazidime. In dogs, they were 13.3% for YM-13115, 62.5% for ceftriaxone, and 86.3% for ceftazidime. In monkeys, they were 22.5% for YM-13115 and 29.3% for ceftriaxone. The 24-h biliary recoveries in rats were 72.2% for YM-13115, 61.8% for ceftriaxone, and 0.63% for ceftazidime.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000378:metabolism*; D001646:Bile / Q000378:metabolism; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000378:metabolism; D002442:Ceftazidime / Q000378:metabolism*; D002443:Ceftriaxone; D002511:Cephalosporins / Q000494:pharmacology; D004285:Dogs; D007275:Injections, Intravenous; D007700:Kinetics; D008253:Macaca mulatta; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002443:Ceftriaxone; C042179:YM 13115; D002442:Ceftazidime; D002439:Cefotaxime